The burden of aging and obesity is urging extended investigation into the molecular mechanisms that underlie chronic adipose tissue inflammation. B cell-targeted therapies are emerging as novel tools to modulate the immune system and thereby mitigate aging and obesity-related metabolic complications.
characterized by sustained low-grade inflammation. Abnormalities in the AT, especially the VAT, lead to the expansion of AT-resident immune cells and infiltration by circulating immune cells. Over the past decade, studies on changes in the AT immune system, especially during obesity [4] and to a lesser extent, aging [5] , has enormously increased. Although the majority of these studies focus on topics related to the polarization of ATmacrophages (ATM) from anti-inflammatory (M2) to pro-inflammatory (M1), as mediated by IFNγ secretion from AT-T cells (ATT) [6] , less abundant but equally strong publications show direct impacts of lymphocytes, predominantly T cells, on AT inflammation and thus AT function and metabolic health in obesity and aging. The pathogenic role of B cells as antigen presenting cells and antibody producers during obesity and aging has been less investigated. Exceptions include diet-induced obesity experiments, which demonstrated that obese B cell-null mice showed improved insulin sensitivity due to the absence of pathogenic IgG and reduced antigen presentation to pro-inflammatory ATT and ATM [7] , as well as reduced AT and circulating leptin levels [8] . Studies in obese subjects showed increased IgG production by subcutaneous adipose tissue (SAT) B cells [9] , consistent with the demonstration of pathogenic IgG in obese mice. Our related work showed that human B cells are essential for promoting Th17 inflammation only in T2D, whereas myeloid cells promote IL-17 production in a disease-independent manner [8] . These studies highlight obesity-mediated derangement in generally anti-inflammatory actions of B cells in AT from young and/or lean individuals, as also evidenced by work showing that B-1a cells and/or regulatory B cells (i.e., Bregs) produce the anti-inflammatory cytokine IL-10 to rescue obese mice from insulin resistance [10] . Together these data indicate B cells are potential targets for ameliorating obesity-induced inflammation, and raise the possibility of key roles in the pathogenic VAT in aging.
Elegant work from Camell and colleagues showed that aged mice expand AAB only in VAT niches, but not in other fat pads or spleen, and that they differ from previously identified splenic aged B cells (ABC) [11, 12] . These VAT B cells niches are housed in so-called fat-associated lymphoid clusters (FALCS), that are induced during inflammation and are highly vascularized to support immune cell trafficking [13] . The authors used whole-mount staining of VAT-FALCS as a tool to provide threedimensional information about the distribution of immune cells therein.
This method generated sophisticated images of aged VAT-FALCS and found that AAB were in close contact with ATM, and that AAB expansion was supported not only by recruitment from lymphatic vessels but also by AAB replication. By depleting AAB, the authors improved insulin sensitivity (but not lipolysis) and reduced T regulatory cells (Treg) frequency and PD1 expression in aged mice. These data raise the possibility that AAB targeting could be exploited to arrest or reverse metabolic declines that associate with age, perhaps as an approach to extend healthspan [14] . The authors also showed that the activation of the Immunometabolism. 2020;2(2):e200011. https://doi.org/10.20900/immunometab20200011 NLRP3 inflammasome, a multiprotein complex responsible for triggering the protease activity that activates both pro-IL-1β and pro-IL-18 to regulate VAT inflammation and remodeling [15] , was essential to increase AAB number, FALCS number and lipolysis by upregulating IL-18 and the IL-1β/IL-1βR axis through post-transcriptional mechanisms. These findings extend the Dixit lab's previous work on the NLRP3 inflammasome, in which nerve-associated aged-ATM induce lipolysis resistance in a NLRP3dependent fashion [16] .
Mechanisms that promote AAB suggest further similarities with AT-B cells in obesity that hinge on critical metabolic regulators like leptin, an adipocyte cytokine that regulates appetite and insulin resistance [17, 18] .
Leptin levels increase in both obesity [19] and aging (75-99 years) [20] , most likely due to the development of leptin resistance in both environments [21, 22] . B cells express the long isoform of the class I cytokine leptin receptor, which is wired to signaling pathways that stimulate B cell proliferation and cytokine secretion [23] and can positively regulate B cell activation in people over 65 years of age [24] .
Taken together, these data raise speculation that leptin may modulate AAB replication in FALCS (Figure 1) , and control B cell number/function in obesity. Additional circumstantial evidence that leptin regulates AAB includes the demonstration that leptin is higher in females versus males [25] and that AAB expansion is higher in aged female mice. Future work aimed at pinpointing similarities/differences in B cell leptin responses will be necessary to test whether B cell physiology convergently evolves in obesity and aging. In this sense, it has been demonstrated that leptin modulates IL-18 secretion in LPS-stimulated monocytes during T2Dmediated inflammation through NLRP3-inflammasome and caspase 1 activation [26] , suggesting that leptin could be also be involved in upregulating IL-18 secretion in AAB. Furthermore, growth hormone receptor (GHR) deficiency improves insulin sensitivity and obesitymediated leptin resistance in humans [27] , and abrogated GHR signaling in mice reduces NLRP3 activation that correlates with pro-longevity effects [28] . Taken together, these data point to leptin as an underlying mediator in reducing ABC and AAB in aged GHR-KO mice.
Although further investigations are needed, especially in humans, Camell and colleague's discovery raises the possibility of using AAB depletion as immunotherapy tool aimed to improve age-associated metabolic complications, such as insulin resistance and lipolysis, with the ultimate goal of extending healthspan. 
